IMDX (Insight Molecular Diagnostics) 3-Year EBITDA Growth Rate : 25.50% (As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is Insight Molecular Diagnostics 3-Year EBITDA Growth Rate?

Insight Molecular Diagnostics's EBITDA per Share for the three months ended in Mar. 2025 was $-0.24.

During the past 3 years, the average EBITDA Per Share Growth Rate was 25.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 20.60% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 11.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Insight Molecular Diagnostics was 34.50% per year. The lowest was -12.10% per year. And the median was 6.40% per year.

Competitive Comparison of Insight Molecular Diagnostics's 3-Year EBITDA Growth Rate

For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Insight Molecular Diagnostics's 3-Year EBITDA Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Insight Molecular Diagnostics's 3-Year EBITDA Growth Rate falls into.

Save Embed

;

Save Embed

;

Insight Molecular Diagnostics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Insight Molecular Diagnostics (NAS:IMDX) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Insight Molecular Diagnostics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Insight Molecular Diagnostics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Insight Molecular Diagnostics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Insight Molecular Diagnostics Inc (NAS:IMDX) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

0KCC:UK

Address

15 Cushing, Irvine, CA, USA, 92618

Website

https://www.oncocyte.com

OncoCyte Corp is a pioneering diagnostics technology company. Its mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers, or payers.

Executives

Broadwood Partners Lp	10 percent owner	BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK NY 10019
Andrew Arno	director	C/O MERRIMAN CURHAN FORD GROUP, INC., 600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108
Josh Riggs	officer: Interim CEO	15 CUSHING, IRVINE CA 92618
John Peter Gutfreund	other: Former Director	767 5TH AVENUE, 44TH FLOOR, NEW YORK NY 10153
Alfred D Kingsley	director	150 E 57TH STREET, NEW YORK NY 10022
Pura Vida Investments, Llc	10 percent owner	512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Lou Silverman	director
James Yang Liu	officer: Controller, PAO	C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
Andrew J. Last	director	3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Jennifer L. Carter	director	C/O DFP SPONSOR LLC, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Ronald Asbury Andrews	director	5791 VAN ALLEN WAY, CARLSBAD CA 92008
Melinda Griffith	director	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Anish M. John	officer: SVP, Finance, and Interim CFO	C/O ONCOCYTE CORPORATION,, 15 CUSHING, IRVINE CA 92618
Li Yu	officer: VP Cntrllr/Prncpl Acctng Offcr	120 NEWPORT CENTER DRIVE., NEWPORT BEACH CA 92660
Efrem Kamen	10 percent owner	C/O PURA VIDA INVESTMENTS, LLC, 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011